Los suplementos de GLP-1 y los medicamentos agonistas del receptor han surgido como opciones teraputicas esenciales para el control del peso, y tambin muestran un gran potencial en el tratamiento de trastornos ms all de la diabetes y la obesidad
21 , 22 The overall size of the trials, however, allows for a sufficient number of participants who are overweight or have Class 1 obesity to characterize the safety and efficacy of retatrutide in this population
Boye KS, Botros FT, Haupt A, Woodward B, Lage MJ
Ethics declarations Conflict of interest Bartlomiej Kwiek reported serving as a clinical study investigator for AbbVie, Amgen inc, Arcutis Biotherapeuthics, Almirall, Aslan, Bristol-Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, Samsung
doi: 10.1053/j.ajkd.2013.10.057
Over the four-year period, the percentage of female patients with a semaglutide or tirzepatide prescription who also had PCOS increased from 4.6% in 2021 to 5.7% in 2025, representing a 23.9% relative increase
